Performance of a Fluticasone Propionate/Salmeterol Xinafoate 3M Taper DPI
|
|
- Christina Floyd
- 6 years ago
- Views:
Transcription
1 3M Drug Delivery Systems Performance of a Fluticasone Propionate/Salmeterol Xinafoate 3M Taper DPI Poster Reprint / Spring 2011 John Simons 1, Herbert Chiou 1, Louis Sigtermans 1, Tom Robison 1, Debra Wright 1, Jacqueline Ganser 1, Steve Stein 1, Les Harrison 1, Paul Ratner 2 1 3M Drug Delivery Systems, St. Paul, MN 2 Sylvana Research, San Antonio TX 3
2 Introduction Introduction In a previous paper, 3M s Taper dry powder inhaler (DPI) design and performance were described (1). This poster builds on that foundation and characterizes the uniformity of excipient-free fluticasone propionate(fp)/salmeterol xinafoate (SX) blends, the uniformity of the coated powder blends, and the performance of a FP/SX 3M Taper DPI. The in vitro results from a FP/SX 3M Taper DPI product are also compared with the 250/50 strength Advair Diskus * product. Table of Contents Methods...1 Blend/Coating Results...2 Performance Resutls...3 Future Work...5 Conclusions...5 References
3 Methods Methods Blending, Blend Uniformity Sampling: The blends were generated using a proprietary 3M process. Post processing samples were taken using customized sample thieves to collect μg of sample. Samples were taken from 20 locations throughout the blend. With regard to SX results, all numbers are reported as salmeterol base (SB) in accordance with how Advair product is labeled. Coating Process, Microstructured Carrier Tape (MCT): An asynchronous roller coating method (1) was used to fill the dimples in the MCT which is the primary packaging component of the Taper DPI device. Based on preliminary studies that were designed to estimate the delivered and fine particle doses of FP/SX blends with Taper, new MCT were manufactured (230 μg/dose [FP+SX] load capacity) to match the fine particle dose of the 250/50 Advair product. Next Generation Impactor (NGI): To measure the particle size distribution of the emitted doses from both the Taper and Advair products, NGIs were operated at 85 LPM (4 KPa pressure drop). Cups were coated to prevent particle bounce. Spring 2011 Performance of a Fluticasone Propionate/Salmeterol Xinafoate 3M Taper DPI 1
4 Blend/Coating Results Blend/Coating Results Blend Results: Table 1 shows the blend uniformity results obtained from a typical FP/SX blend (target blend ratio 6.3:1). Even when sampling a very small amount of the blend (~20-25 μg) relative to the size of the intended dose (~230 μg), a RSD of less than 2% was achieved. The results clearly demonstrate the capability of the blending process to mix excipient-free blends of micronized powders. In this particular example, the batch size was 80 g. Table 1: Blend uniformity of a typical FP/SX blend (n=20, sample size μg). Sample FP SB Ratio Ave :1 SD 0.1 RSD 1.7% Retention of Blend Uniformity: As with any blend there is the potential for segregation to occur if not properly handled or stored post processing. Because the powder feeding and coating processes for the Taper device impart some energy into the blends, it is necessary to demonstrate that the blends will remain unchanged or are changed in a predictable, reproducible manner. Table 2 lists the results of coating four separate blends on four separate days using the coating process described above. Blend 4 in Table 2 is the same blend referenced in Table 1. Table 2: Uniformity of coated microstructured carrier tape (MCT) with four FP/SX blends (n=36, 27, 72, 10) on four different days. Blend/Run 1 Blend/Run 2 Blend/Run 3 Blend/Run 4 Sample FP SB Ratio FP SB Ratio FP SB Ratio FP SB Ratio Ave : : : :1 SD RSD 2.8% 3.0% 1.3% 2.3% 2.3% 0.7% 3.3% 2.9% 1.7% Based on the content results, the powder coating method provides very good reproducibility for coating excipient-free FP/SX blends (within as well as across coating runs). There was also no significant change in the blend ratio due to coating, thus indicating that the powder feeding and coating processes used for Taper are compatible with the blends and will not cause them to segregate under normal processing conditions. Because of the cohesive nature of micronized powders and the similar particle size distributions (PSD) and densities of most relevant APIs considered for inhalation, the Taper coating process is expected to work well for a wide range of excipient-free API blends. Spring 2011 Performance of a Fluticasone Propionate/Salmeterol Xinafoate 3M Taper DPI 2
5 Product Performance Results Product Performance Results Product Performance: The NGI results of the FP/SX Taper product were compared with the 250/50 strength Advair product in Tables 3/4 and Figure 1. As intended, the fine particle masses (FPM) are well matched. Also as expected, the greatest differences in the data sets are the delivered doses from each device and the amount of FP/SX collected on the throat and pre-separator of the NGI. Table 3: Comparison of Taper and Advair Diskus in vitro data Fluticasone Propionate Salmeterol Base Delivered FPM < 5 µm MMAD Delivered FPM < 5 µm MMAD Dose, µg µg % µm Dose, µg µg % µm Taper Advair Figure 1: Comparison of NGI profiles for 3M Taper and Advair Diskus devices Drug Deposition (mcg) Fluticasone Propionate Particle Size Distribution by NGI Drug Depostion (mcg) Taper 6:1 Advair Diskus 250/50 Expanded View Cup 1 Cup 2 Cup 3 Cup 4 Cup 5 Cup 6 Cup 7 MOC 0 T + PS Cup 1 Cup 2 Cup 3 Cup 4 Cup 5 Cup 6 Cup 7 MOC Salmeterol Base Particle Size Distribution by NGI Drug Deposition (mcg) Drug Depositon (mcg) Taper 6:1 Advair Diskus 250/50 Expanded View Cup 1 Cup 2 Cup 3 Cup 4 Cup 5 Cup 6 Cup 7 MOC 0 T + PS Cup 1 Cup 2 Cup 3 Cup 4 Cup 5 Cup 6 Cup 7 MOC Spring 2011 Performance of a Fluticasone Propionate/Salmeterol Xinafoate 3M Taper DPI 3
6 Product Performance Results Cont. Product Performance Results Cont. Table 4. Average FP/SB NGI cup deposition for Advair and Taper (n = 5, μg) and normalized amount of FP/SB deposited from Taper device relative to Advair; (T/Adv%) = [Taper / Advair * 100] T+PS Cup 1 Cup 2 Cup 3 Cup 4 Cup 5 Cup 6 Cup 7 MOC FP Advair Taper T/Adv% 46% 77% 105% 96% 88% 91% 85% SB Advair Taper T/Adv% 29% 70% 89% 100% 96% 81% 0% As the data show, the 3M Taper device can be used to match a specified respirable dose target very accurately. As designed, the 3M Taper device is more efficient than the Advair Diskus product. As a result, less FP/SX needs to be loaded to deliver a set amount of drug and less drug is delivered from the device. In this specific example, only ~186 μg/dose for FP (~75% of Advair) and ~31 μg/dose of SB (~60% of Advair) are required to deliver the same respirable masses of FP and SB. Overall, there is good agreement between the Advair and FP/SX Taper products with regard to the amount of FP/SB collected on cups 1 to MOC. Although Advair begins with a 5:1 loading ratio for FP/SB (250 μg /50 μg), the respirable mass ratio for FP/SB is 6:1 (48 μg /8 μg). Since Taper maintains the same loaded and delivered ratios of FP/SB, it was necessary to start with a 6:1 (186 μg /31 μg) blend in order to match the 6:1 respirable mass ratio (47.9 μg /7.9 μg) of the Advair product. Spring 2011 Performance of a Fluticasone Propionate/Salmeterol Xinafoate 3M Taper DPI 4
7 Future Work Future Work Based on the results of this work, a clinical protocol has been written to explore the capability of the 3M Taper DPI to deliver a combination therapy to mild/moderate asthmatic patients with demonstrated reversibility. Per the protocol, sixteen subjects will receive two treatments separated by 7-16 days, according to a randomized, two-period crossover design: The reference treatment will be one inhalation from an Advair Diskus product (250/50 strength); the test treatment will be one inhalation from the 3M Taper device which contains approximately the same fine particle mass of each drug per dose. Pulmonary function and pharmacokinetics will be followed over 12.5 hr. Production of clinical supplies has been completed. Conclusions Conclusions As demonstrated by the results presented, 3M s Taper technology is capable of handling excipient-free powder blends and can be customized to match specific dosing targets. In comparing the performance of a FP/SX Taper product to Advair, there is a clear advantage of improved delivery efficiency which corresponds to less drug being required to deliver a target amount of drug to a patient s lungs. References References 1. Stein, S., Hodson, D., Alband, T., Sitz, R., Robison, T., Wang, Z. Chiou, H., Simons, J., McNally, R., and Ganser, J. (2010) The 3MTM Taper Dry Powder Inhaler Device, Bryon, P.R., Byron, P.R., Peart, J., Suman, J.D., Farr, S.J., Young, P.M., (eds), Respiratory Drug Delivery 2010, Vol 2, pp Spring 2011 Performance of a Fluticasone Propionate/Salmeterol Xinafoate 3M Taper DPI 5
8 Drug Delivery Systems Drug Delivery Systems Drug Delivery Systems Drug Delivery Systems 3M Center, building E-10 St. Paul, MN USA FAX M.com/MTSDelivery 3M House, Morley Street, Loughborough, Leicestershire, LE11 1EP England +44 (0) FAX +44 (0) M.com/MTSDelivery 33-1, Tamagawadai 2-chrome Setagaya-ku, Tokyo Japan (81) FAX (81) M.com/MTSDelivery 3M Innovation Singapore Pte Ltd 1 Yishun Avenue 7 Singapore (65) FAX (65) M.com/MTSDelivery 3M All rights reserved. 3M is a trademark of 3M Company. Advair Diskus is a registered trademark of GlaxoSmithKline.
Dry Powder Inhaler. Developing an Efficient. 3M Conix DPI. White Paper / Spring Proven Solutions that Enable Your Success
3M Drug Delivery Systems Developing an Efficient Dry Powder Inhaler 3M Conix DPI White Paper / Spring 2011 Proven Solutions that Enable Your Success Introduction introduction Inhalation drug delivery has
More informationDevice Design Similarity
Device Design Similarity Dave Parkins Director DPI Product Development PQRI Workshop on Demonstrating Bioequivalence of Locally Acting Orally Inhaled Drug Products. Bethesda March 9-10, 2009 Device Similarity
More informationIPAC-RS/UF Orlando Inhalation Conference March 20, S.T. Horhota 1, C.B. Verkleij 2, P.J.G. Cornelissen 2, L. Bour 3, A. Sharma 3, M.
IPAC-RS/UF Orlando Inhalation Conference March 20, 2014 Case Study: Pharmacokinetics and Pharmacodynamics of Tiotropium and Salmeterol Following Parallel Administration in COPD Patients Using Different
More informationRDD Europe 2011 Workshop 4 May 2011
RDD Europe 2011 Workshop 4 May 2011 This file represents the slides presented on May 4, 2011 by 3M Drug Delivery Systems at the RDD Europe 2011 Conference in Berlin, Germany. Slides have been modified
More informationINTEGRATED DESIGN SPACE TO DEVELOP BETTER DPI FORMULATIONS
INTEGRATED DESIGN SPACE TO DEVELOP BETTER DPI FORMULATIONS Here, Filipa Maia, PhD, and Maria Palha, MSc, both Scientists at Hovione, report a study whose objective was to establish relationships between
More informationEverything for Inhalation
Everything for Inhalation Everything for Inhalation Inhalation drug product development at Hovione has a strong focus on formulation for Dry Powder Inhalers (DPI), particularly for capsule-based and reservoir-based
More informationPublic Assessment Report Scientific discussion. Salmeterol/Fluticasone Sandoz (salmeterol xinafoate, fluticasone propionate) SE/H/1323/03/DC
Public Assessment Report Scientific discussion Salmeterol/Fluticasone Sandoz (salmeterol xinafoate, fluticasone propionate) SE/H/1323/03/DC This module reflects the scientific discussion for the approval
More informationYear in review. Vit Perlik Director of Regulatory Science and Clinical Development
Year in review Vit Perlik Director of Regulatory Science and Clinical Development Content Year in review Covering September 2013 to September 2014 Where the regulation goes selection of events for illustration
More informationRespiratory. Martin Jetzer DDL27 Edinburgh December 2016
Respiratory Investigating the Effect of the Force Control Agent Magnesium Stearate in Fluticasone Propionate Dry Powder Inhaled Formulations with Single Particle Aerosol Mass Spectrometry Martin Jetzer
More informationEquivalence Evaluation of Valved Holding Chambers (VHCs) with Albuterol Pressurized Metered Dose Inhaler (pmdi)
Respiratory Drug Delivery Europe 2017 Nagel and Suggett Equivalence Evaluation of Valved Holding Chambers (VHCs) with Albuterol Pressurized Metered Dose Inhaler (pmdi) Mark W. Nagel and Jason A. Suggett
More informationPatient. Device Clinician. Safety & efficacy
Patient Device Clinician Formulation Safety & efficacy 1. Modified from Daley-Yates et al., Expert Opin. Drug Deliv. 2011: 8(10):1297-1308 2. Modified from Laube et al., Eur Respir J 2011; 37: 1308 1331
More informationPublic Assessment Report Scientific discussion. Flumetor (salmeterol xinafoate/fluticasone propionate) SE/H/1068/01-02/DC
Public Assessment Report Scientific discussion Flumetor (salmeterol xinafoate/fluticasone propionate) SE/H/1068/01-02/DC This module reflects the scientific discussion for the approval of Flumetor. The
More informationRDD Europe 2009 Workshop
RDD Europe 2009 Workshop 20 May 2009, Lisbon, Portugal This file is a redacted version of the presentation used during the Workshop and is suitable for electronic distribution. An Introduction to Differentiating
More informationCaption: The equipment required for testing Fluticasone Propionate (FP) Inhalation Powder in line with a new product-specific monograph (USP36-NF31).
Product-specific FDA guidance, and product-specific pharmacopeial monographs, point to the use of test equipment, some of which isn t included in the general USP/Ph. Eur. chapters for orally inhaled products
More informationBiopharmaceutics of Non-Orally Administrated Drugs
Biopharmaceutics of Non-Orally Administrated Drugs Robert Lionberger, Ph.D. Deputy Director for Science (acting) Office of Generic Drugs, FDA November 21, 2013 AAPS Webinar Opinions expressed in this presentation
More informationCase Study 1: Pharmaceutical Development of EXUBERA
Case Study 1: Pharmaceutical Development of EXUBERA Nancy Harper, PhD Research Fellow, Parenteral Development Center of Emphasis Pfizer Global R&D IPAC-RS Conference November 2006 1 EXUBERA Insulin human
More informationDraft Guidance on Fluticasone Propionate; Salmeterol Xinafoate. Fluticasone Propionate; Salmeterol Xinafoate. Powder/Inhalation
Reprinted from FDA s website by EAS Consulting Group, LLC Contains Nonbinding Recommendations Draft Guidance on Fluticasone Propionate; Salmeterol Xinafoate This draft guidance, once finalized, will represent
More informationTEPZZ _7584 A_T EP A1 (19) (11) EP A1 (12) EUROPEAN PATENT APPLICATION. (51) Int Cl.: A61K 9/00 ( ) A61K 31/439 (2006.
(19) TEPZZ _784 A_T (11) EP 3 17 842 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: 07.06.17 Bulletin 17/23 (1) Int Cl.: A61K 9/00 (06.01) A61K 31/439 (06.01) (21) Application number: 1197874.9
More informationThe influence of lactose particle size on dry powder inhalation performance
The influence of lactose particle size on dry powder inhalation performance MCC Starch Lactose Inhalation Superdisintegrants 1 Introduction In most dry powder inhalation (DPI) formulations carriers are
More informationUnderstanding cascade impaction and its importance for inhaler testing
Understanding cascade impaction and its importance for inhaler testing Mark Copley, Technical Sales Manager Inhalation product development is an important area of activity for the pharmaceutical sector.
More informationUse of Math Modelling to Understand Delivery of Biopharmaceutical Molecules to the Lung
Use of Math Modelling to Understand Delivery of Biopharmaceutical Molecules to the Lung Nia Stevens 9 th November 2016 Thanks to Richard Kaye, James Mitchell, Dave Prime at GSK Bahman Asgharian and Owen
More informationPartner with the Global Leader in Drug Delivery Systems.
3M DRUG DELIVERY SYSTEMS Partner with the Global Leader in Drug Delivery Systems. Hurlingham, Argentina Manufacturing Facility Experts at Commercializing Innovation 3M is a global innovation company that
More informationPartner with the Global Leader in Drug Delivery Systems.
3M DRUG DELIVERY SYSTEMS Partner with the Global Leader in Drug Delivery Systems. Hurlingham, Argentina Manufacturing Facility Experts at Commercializing Innovation Drug Delivery Systems: It s in the detail
More informationInhaled Corticosteroids for the Treatment of Chronic Asthma in Adults & Adolescents aged 12 years & over
Manufacturer Submission To The National Institute for Health and Clinical Excellence By GlaxoSmithKline UK Inhaled Corticosteroids for the Treatment of Chronic Asthma in Adults & Adolescents aged 12 years
More informationPartner with the Global Leader in Drug Delivery Systems
3M DRUG DELIVERY SYSTEMS Partner with the Global Leader in Drug Delivery Systems Loughborough, United Kingdom Manufacturing Facility Experts at Commercializing Innovation 3M: Transforming New Ideas into
More informationGo With the Flow REGULATORY LANDSCAPE. Mark Copley at Copley Scientific
Go With the Flow Image: Guzel Studio shutterstock.com Increasing global requirements for efficacious, inexpensive products to treat respiratory illnesses are driving the development of inhaled generics.
More informationEPAG Sponsored Workshop on Abbreviated Impactor Measurement (AIM) and Efficient Data Analysis (EDA) Concepts in Inhaler Testing. Overview of AIM EDA
EPAG Sponsored Workshop on Abbreviated Impactor Measurement (AIM) and Efficient Data Analysis (EDA) Concepts in Inhaler Testing Overview of AIM EDA Jolyon Mitchell 1 and Mark Copley 2 1 Trudell Medical
More informationFormulation Considerations for Inhaled Products
Formulation Considerations for Inhaled Products Formulation Considerations of Inhaled Products Inhalation Therapy Nebulizers and Formulations Dry Powder Inhalers and Formulations Metered Dose Inhalers
More informationInhalation Product Research at FDA
Inhalation Product Research at FDA Changning Guo Ph. D., Chemist Division of Pharmaceutical Analysis FDA/CDER/OPS/OTR 2016 GPhA CMC workshop, May 17, 2016 Disclaimer: This presentation reflects the views
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationINSPIRE: A Phase 3 Open-Label, Multicenter Study to Evaluate the Safety and Tolerability of LIQ861 in Pulmonary Arterial Hypertension (PAH)
INSPIRE: A Phase 3 Open-Label, Multicenter Study to Evaluate the Safety and Tolerability of LIQ861 in Pulmonary Arterial Hypertension (PAH) N. S. Hill; J. P. Feldman; S. Sahay; D. J. Levine; R. F. Roscigno;
More information040716_ANDI_VENTIS WEBSITE(new) Printout 1. HOME PAGE. Welcome to our world of Dry Powder Inhalers!
1. HOME PAGE Welcome to our world of Dry Powder Inhalers! Andi-Ventis Ltd, established in 2001 is a joint venture between Medochemie Ltd, Cyprus and Miat SpA Italy, founded to carry out the pharmaceutical
More informationAssessing Quality of Inhaled Products And Links to Efficacy and Safety
Assessing Quality of Inhaled Products And Links to Efficacy and Safety Prasad Peri, PhD ONDQA 2011 IPAC-RS Conference Bringing Value To The Patient In A Changing World March 30, 2011 1 Outline of the Presentation
More informationNEBULIZERS, METERED DOSE INHALERS, AND DRY POWDER INHALERS
NEBULIZERS, METERED DOSE INHALERS, AND DRY POWDER INHALERS Douglas S. Gardenhire, Ed.D, RRT-NPS MODULE 1 Manipulate Small Volume Nebulizers by Order or Protocol 1 Objectives for Module 1 At the end of
More informationCurrent Challenges and Opportunities in Demonstrating Bioequivalence
Current Challenges and Opportunities in Demonstrating Bioequivalence Gur Jai Pal Singh, Ph.D. Watson Laboratories, Inc. Corona, California, USA Demonstrating Bioequivalence of Locally Acting Orally Inhaled
More informationCOMPARISON OF THE RESPIRABLE FRACTION FROM THREE DIFERENT DPI DEVICES
COMPARISON OF THE RESPIRABLE FRACTION FROM THREE DIFERENT DPI DEVICES Miriam Sanz Cermeño and Helena Maria Cabral Marques UCTF, Faculdade de Farmácia, Universidade de Lisboa, PORTUGAL 1. Introduction Inhalation
More informationPatricia KP Burnell Inhalation Product Development
Patricia KP Burnell Inhalation Product Development Inhaled products: types, development The critical parameters In-vitro testing Ex-vivo testing What dose? Product Development: drug medicine Safety and
More informationResearch Article. *Corresponding author Mahesh M.Giri
Scholars Academic Journal of Pharmacy (SAJP) ISSN 2320-4206 Sch. Acad. J. Pharm., 2013; 2(3):260-267 Scholars Academic and Scientific Publisher (An International Publisher for Academic and Scientific Resources)
More informationImproved Aerosol Deposition Profiles from Dry Powder Inhalers
1 University of Hertfordhire Improved Aerosol Deposition Profiles from Dry Powder Inhalers Submitted to the University of Hertfordshire in partial fulfilment of the requirements of the degree of Doctor
More informationPredictive modeling of deposition, dissolution, absorption and systemic exposure
Predictive modeling of deposition, dissolution, absorption and systemic exposure IPAC-RS/UF Orlando Inhalation Conference March 20, 2014 Per Bäckman and Bo Olsson, AstraZeneca R&D, Mölndal Sweden The views
More informationAssessing the role of breathing simulators in OIP testing
As first AppeAred in Inhalation April 2014 www.inhalationmag.com Assessing the role of breathing simulators in OIP testing Exploring how the application of patient-representative inhalation profiles can
More informationGeneric Inhaled Medications
Generic Inhaled Medications Financial Interest Disclosure (over the past 24 months) Irvin Mayers Company Speaker Advisory Research Medimmune Novartis GSK Boehringer Ingelheim CADTH Health Canada Financial
More informationEffect of Device Design and Formulation on the In Vitro Comparability for Multi-Unit Dose Dry Powder Inhalers
The AAPS Journal, Vol. 17, No. 5, September 2015 ( # 2015) DOI: 10.1208/s12248-015-9775-z Research Article Theme: Current Scientific and Regulatory Approaches for Development of Orally Inhaled and Nasal
More informationA Real Case Comparison of Average and Population Bioequivalence for Evaluation of APSD data
A Real Case Comparison of Average and Population Bioequivalence for Evaluation of APSD data IPAC-RS/UF Orlando Inhalation Conference March 18-20, 2014 Dennis Sandell, S5 Consulting Contents The data brief
More informationBioequivalence of Inhaled Corticosteroids. -with emphasis on Pharmacokinetic Tools.
Bioequivalence of Inhaled Corticosteroids -with emphasis on Pharmacokinetic Tools? hochhaus@ufl.edu Topics related to Bioequivalence 10-60 % Deposited in lung Complete absorption from the lung Cl muc Mouth
More informationThe abbreviated impactor measurement concept
AS APPEARED IN Inhalation JUNE 2009 www.inhalationmag.com The abbreviated impactor measurement concept A potentially faster and more precise way to assess quality of inhaled drug products Jolyon P. Mitchell,
More informationResearch Article. De-agglomeration Effect of the US Pharmacopeia and Alberta Throats on Carrier-Based Powders in Commercial Inhalation Products
The AAPS Journal, Vol. 17, No. 6, November 2015 ( # 2015) DOI: 10.1208/s12248-015-9802-0 Research Article De-agglomeration Effect of the US Pharmacopeia and Alberta Throats on Carrier-Based Powders in
More informationUniversity of Groningen. Technology in practice Lexmond, Anne
University of Groningen Technology in practice Lexmond, Anne IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document
More informationrj.;!i U.S. FOOD & DRUG - ADMIN ISTRATION
rj.;!i U.S. FOOD & DRUG - ADMIN ISTRATION HAR 1 0 2017 Anthony Maffia Vice President, Regulatory Affairs Sandoz Inc. 1 00 College Road West Princeton, NJ 08540 Dear Mr. Maffia: Re: Docket No. FDA-2016-P-3356
More informationAEROSOL THERAPY: THE PRACTICALITIES
AEROSOL THERAPY: THE PRACTICALITIES Lester I. Harrison, PhD Section Head, Clinical Pharmacokinetics, 3M Pharmaceuticals, 3M Center 270-3S-05, St. Paul, MN, USA 55144 liharrison@mmm.com Introduction: Horses,
More informationAdapting Pharmacopeial Testing for Pharmaceutical Equivalence Studies. Julie D. Suman, Ph.D. March 29, 2016
Adapting Pharmacopeial Testing for Pharmaceutical Equivalence Studies Julie D. Suman, Ph.D. March 29, 2016 AGENDA Regulatory Approaches for Bioequivalence (BE) Compendial Testing Vs Pharmaceutical Equivalence
More informationIMPROVING THE REALISM AND RELEVANCE OF MOUTH-THROAT MODELS FOR INHALED PRODUCT TESTING
IMPROVING THE REALISM AND RELEVANCE OF MOUTH-THROAT MODELS FOR INHALED PRODUCT TESTING In this piece, Mark Copley, Sales Director of Copley Scientific, provides some background on mouth-throat models for
More informationCAPSULE-BASED DRY POWDER INHALERS, AN OPTIMAL SOLUTION FOR DIFFERENT INSPIRATIONAL RATES
xxx Qualicaps CAPSULE-BASED DRY POWDER INHALERS, AN OPTIMAL SOLUTION FOR DIFFERENT INSPIRATIONAL RATES There is a wide range of devices available to deliver inhalation therapies, but there is increasing
More informationQualifying Container Closure Systems for OINDP: Current & Future Regulatory Expectations. Julie D. Suman, Ph.D. November 14, 2014
Qualifying Container Closure Systems for OINDP: Current & Future Regulatory Expectations Julie D. Suman, Ph.D. November 14, 2014 Objectives Container-Closure System Attributes Extractables Regulatory Expectations
More informationPulmonary deposition of inhaled drugs
Pulmonary deposition of inhaled drugs Federico Lavorini Dept. Experimental and Clinical Medicine Careggi University Hospital Florence - Italy Presenter Disclosures F.L. has received in the last 5 years
More informationThe pulmonary route is gaining increasing
ELECTRONICALLY REPRINTED FROM FEBRUARY 2014 Pulmonary Drug Delivery Particle Engineering for Inhaled Therapeutics Moderated by Adeline Siew, PhD Industry experts discuss the various factors affecting drug
More informationUnderstanding Regulatory Global Requirements for Nasal Drug Products. Julie D. Suman, Ph.D. April 8, 2016
Understanding Regulatory Global Requirements for Nasal Drug Products Julie D. Suman, Ph.D. April 8, 2016 AGENDA NDA vs ANDA Regulatory Approaches for Bioequivalence (BE) FDA Drug Specific Guidances FDA,
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE PHARMACEUTICAL QUALITY OF INHALATION AND NASAL PRODUCTS
European Medicines Agency Inspections London, 16 February 2005 Doc Ref.: EMEA/CHMP/QWP/49313/2005 corr. COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE PHARMACEUTICAL QUALITY OF
More informationInfluence of blender type on the performance of ternary dry powder inhaler formulations
Institute of Pharmacy Kiel University Influence of blender type on the performance of ternary dry powder inhaler formulations Mats Hertel Theoretical background Binary formulation: 1 st blending Ternary
More informationCLINICAL RELEVANCE OF IN VITRO PARTICLE SIZING DATA. Steve Newman, PhD Nottingham, UK November 2006
IPAC-RS Conference 6-8 November 2006 CLINICAL RELEVANCE OF IN VITRO PARTICLE SIZING DATA Steve Newman, PhD Nottingham, UK November 2006 IPAC-RS Conference 6-8 November 2006 1 EFFECT OF PARTICLE SIZE ON
More informationFigure 1: SEM Mannogem EZ (1000x)
Carrier-Mixing of Mannogem EZ with Micronized Low dose Furosemide: Uniformity of dosage unit study Sunil Kumar N *, John K Tillotson, Praveen Saligram, Robert Duffy SPI Pharma Inc. Introduction: To produce
More informationDual-controller therapy, or combinations REVIEW DUAL-CONTROLLER REGIMENS I: DATA FROM RANDOMIZED, CONTROLLED CLINICAL TRIALS.
DUAL-CONTROLLER REGIMENS I: DATA FROM RANDOMIZED, CONTROLLED CLINICAL TRIALS Samy Suissa, PhD ABSTRACT Dual-controller therapy, or combinations of 2 or more pharmacotherapies with complementary mechanisms
More informationPublic Assessment Report Scientific discussion. Salflumix Easyhaler (fluticasone propionate, salmeterol xinafoate) SE/H/1692/01-02/DC
Public Assessment Report Scientific discussion Salflumix Easyhaler (fluticasone propionate, salmeterol xinafoate) SE/H/1692/01-02/DC This module reflects the scientific discussion for the approval of Salflumix
More informationTesting Inhaled Generics
Generic Bioequivalence Testing Inhaled Generics By Mark Copley at Copley Scientific New product-specific FDA guidance and USP monographs support the development of popular inhaled products. This article
More informationTRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol) aerosol powder
TRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol) aerosol powder Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific
More informationMDI. Recommended Equipment
1 x DUSA for MDIs (Silicone Seals) 1 x Base Plate MDI 1 x DUSA for MDIs (Silicone Seals) 9 x Spare Collection Tubes for MDIs 18 x Spare Rinsing Caps for MDIs 1 x Stand for 10 Collection Tubes 1 x Waste
More informationIVIVC in Pediatric OIPs
IPAC-RS/UF Orlando Conference 2014 March 20, 2014 IVIVC in Pediatric OIPs Herbert Wachtel Declaration of Conflicts of Interest H. Wachtel is employee of Boehringer Ingelheim Pharma GmbH & Co. KG, Germany.
More informationWhat You Need to Know about Metered-Dose Inhalers and the HFA Propellant
What You Need to Know about Metered- Inhalers and the HFA Propellant There are a number ways to deliver inhaled medication. They include: Metered-dose inhaler () Metered-dose inhaler with spacer/holding
More informationChallenges in Nonclinical Development of Inhalation Drug Products
Challenges in Nonclinical Development of Inhalation Drug Products Luqi Pei, Ph.D. Senior Pharmacologist DPARP, CDER August 6, 2015 Rockville, MD Disclaimer This speech reflects the views of the speaker
More informationWhat Do Cascade Impaction Measurements Tell Us: In Vitro Aspects. Context of Presentation
What Do Cascade Impaction Measurements Tell Us: In Vitro Aspects Jolyon P. Mitchell, Ph.D. Trudell Medical International London, Canada IPAC-RS Conference November 2006 1 Context of Presentation This talk
More informationAdvance in inhaler technique: changes in delivery devices, Authorized Generics, and Advance in technology for monitoring inhaler adherence
Advance in inhaler technique: changes in delivery devices, Authorized Generics, and Advance in technology for monitoring inhaler adherence Bruce Brown, MS, RRT, AE-C Nemours Healthcare System Disclosures
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Seebri Neohaler) Reference Number: CP.CPA.150 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy
More informationSELECTION AND VALIDATION OF CASCADE IMPACTOR TEST METHODS
Respiratory Drug Delivery IX, 2004 Byron et al. SELECTION AND VALIDATION OF CASCADE IMPACTOR TEST METHODS Peter R. Byron, 1 R. Harris Cummings, 2 Steven C. Nichols, 3 Guirag Poochikian, 4 Michael J. Smurthwaite,
More informationThe unlocked synergy of DFE Pharma MCC
The unlocked synergy of DFE Pharma MCC We are DFE Pharma We are the global leader in excipient solutions. We develop, produce and market excipients for oral solid dose and dry powder inhalation formulations.
More informationPackage ICSpkTS. R topics documented: September 4, Type Package
Package ICSpkTS September 4, 2012 Type Package Title Simulation of pharmacokinetic trials after administration of inhaled corticosteroids. Version 1.0 Date 2012-09-04 Author Benjamin Weber Maintainer Benjamin
More informationUse of Target Tissue Concentrations in PK-PD Modeling of Inhaled Drugs Ramon Hendrickx, AstraZeneca, RIA IMed Gothenburg, Sweden
Use of Target Tissue Concentrations in PK-PD Modeling of Inhaled Drugs Ramon Hendrickx, AstraZeneca, RIA IMed Gothenburg, Sweden IQ DMPK Leadership Group 31 May 2017 What s On? Lung as target organ Benefit
More informationEPAG Perspective - Regulatory Advances Related to Nasal Spray Pumps. Dr G.Williams Nasal Drug Delivery Management Forum London, 15 Apr 2010
1 EPAG Perspective - Regulatory Advances Related to Nasal Spray Pumps Dr G.Williams Nasal Drug Delivery Management Forum London, 15 Apr 2010 Overview 2 EPAG, what is it?, background, this project Regulatory
More informationCombination DPI DEVICES TECHNIQUES,PRIMING & CARE
Combination DPI DEVICES TECHNIQUES,PRIMING & CARE Lisa Romard, MS, RN, CPNP, ANP, AE- C Disclosures: This presentation and clinical recommendations support best available evidence from medical literature.
More informationAnnex I. Scientific conclusions and grounds for refusal presented by the European Medicines Agency
Annex I Scientific conclusions and grounds for refusal presented by the European Medicines Agency Scientific conclusions and grounds for refusal presented by the European Medicines Agency Overall summary
More informationProcess Drift and it s Resolution in the Manufacture of Drug Products. MDI s and DPI s Metered Dose Inhalations and Dry Powder Inhalations
Process Drift and it s Resolution in the Manufacture of Drug Products MDI s and DPI s Metered Dose Inhalations and Dry Powder Inhalations Ed Warner, Merck MMD December 2, 2010 PQRI-FDA Workshop on Process
More informationSTARCH Proven and Trusted Excipient for Performance and Versatility EXCIPIENTS. Effective and economical disintegrant
EXCIPIENTS STARCH 1500 Proven and Trusted Excipient for Performance and Versatility Effective and economical disintegrant Excellent stability for moisture sensitive drugs Manufactured exclusively for the
More informationEP A1 (19) (11) EP A1 (12) EUROPEAN PATENT APPLICATION. (43) Date of publication: Bulletin 2008/29
(19) (12) EUROPEAN PATENT APPLICATION (11) EP 1 944 018 A1 (43) Date of publication: 16.07.2008 Bulletin 2008/29 (21) Application number: 07000425.4 (51) Int Cl.: A61K 9/14 (2006.01) A61K 31/4704 (2006.01)
More informationResearch Article Formulation and Evaluation of Combination Dry Powder for Inhalation: Influence of Crystalline Excipient
Research Article Formulation and Evaluation of Combination Dry Powder for Inhalation: Influence of Crystalline Excipient Shah Vishal Vilas*, Shah Nutan Dhanpal and Patil Smita Jagganath Appasaheb Birnale
More informationThe clinical effectiveness and costeffectiveness. treatment of chronic asthma in children under the age of 12 years
The clinical effectiveness and costeffectiveness of corticosteroids for the treatment of chronic asthma in children under the age of 12 years Submission of evidence from AstraZeneca UK Ltd regarding the
More informationShould you have any questions, please contact Ravi Ravichandran, Principal Scientific Liaison ( or
Fluticasone Propionate and Salmeterol Inhalation Powder Type of Posting Posting Date Targeted Official Date Notice of Intent to Revise 13 Dec 2018 To Be Determined, Revision Bulletin Expert Committee Chemical
More informationIPAC-RS/RDD 2016 Symposium: Meeting the Quality Challenge for Orally Inhaled Drug Products
Correlating the In Vitro Dissolution Behavior of Inhalation and Nasal Drug products with In Vivo Performance: Pitfalls and Potential Solutions using the Transwell System IPAC-RS/RDD 2016 Symposium: Meeting
More informationCURRICULUM VITAE KENNETH D. CHINSKY, M.D.
KENNETH D. CHINSKY, M.D. Chest Diseases of Northwestern PA 3580 Peach Street, Suite 103A Erie, PA 16508 www.chestdiseases.yourmd.com Phone: (814) 864-4755 FAX: (814) 864-5430 Email: Sigsbee@aol.com Home
More informationINTRODUCTION. Asthma Drug Delivery - 1
Asthma Drug Delivery Laboratory Experiment Developed by: Alex Jannini, David Krause, Heather Malino and Kevin Sweeney, Rowan University, Department of Chemical Engineering Edited by: C. Stewart Slater
More informationAssessment of Low Dose Content Uniformity of Indomethacin in Excipient Blends Using FT-Raman Mapping Spectroscopy
Starch 1500 Application Data Partially Pregelatinized Maize Starch Assessment of Low Dose Content Uniformity of Indomethacin in Excipient Blends Using FT-Raman Mapping Spectroscopy OBJECTIVE To characterize
More informationConsiderations for Evaluation of Bioequivalence and Interchangeability of Orally Inhaled Products
Considerations for Evaluation of Bioequivalence and Interchangeability of Orally Inhaled Products Sven Stegemann Sept 16, 2015 Institute for Process and Particle Engineering, Pharmaceutical Engineering
More informationASTHMA TREATMENT AND THE HPA AXIS
ASTHMA TREATMENT AND THE HPA AXIS Paul A. Greenberger, M.D. 7/12/2010 10:30-10:50 10:50 Objectives To review HPA axis suppression and its clinical significance in adults and children To describe methods
More informationyour breathing problems worsen quickly. you use your rescue inhaler, but it does not relieve your breathing problems.
MEDICATION GUIDE ADVAIR DISKUS [ad vair disk us] (fluticasone propionate and salmeterol inhalation powder) for oral inhalation What is the most important information I should know about ADVAIR DISKUS?
More informationMEDICATION GUIDE. ADVAIR [ad vair] HFA 45/21 (fluticasone propionate 45 mcg and salmeterol 21 mcg) Inhalation Aerosol
MEDICATION GUIDE ADVAIR [ad vair] HFA 45/21 (fluticasone propionate 45 mcg and salmeterol 21 mcg) Inhalation Aerosol ADVAIR HFA 115/21 (fluticasone propionate 115 mcg and salmeterol 21 mcg) Inhalation
More informationSpray-Drying Formulation + Process Development Advances
Spray-Drying Formulation + Process Development Advances Expand Opportunities for Formulations Via Intranasal and Pulmonary Delivery authors Jeff Breit, Ph.D. Frederique Bordes-Picard Dominique Cade, Ph.D.
More informationYOUR ORAL SOLID DOSE. In pursuit of excipient excellence
YOUR ORAL SOLID DOSE DFE Pharma globally supplies a unique, broad portfolio of key excipients including lactose, MCC, superdisintegrants and starches. Innovative products such as SuperTab 24AN and SuperTab
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationInhalation Therapy. Inhalation Therapy
Matching Device and Patient Matching Patient to the Device Søren Pedersen University of Southern Denmark Kolding Hospital Anatomical factors (age) Training and education Delivered dose Psycomotor skills
More informationMisty Max 10 nebulizer
AirLife brand Misty Max 10 nebulizer Purpose Introduction Delivery of nebulized medication to the lungs is a complex process dependant upon a variety of clinical and device-related variables. Patient breathing
More informationPublic Assessment Report Scientific discussion SE/H/1689/01/DC
Public Assessment Report Scientific discussion Budesonide/Formoterol Sandoz (budesonide, formoterol fumarate dehydrate) SE/H/1689/01/DC This module reflects the scientific discussion for the approval of
More informationOVERVIEW OF EFFECTIVE DATA ANALYSIS (EDA)
OVERVIEW OF EFFECTIVE DATA ANALYSIS (EDA) Terrence P. Tougas on behalf of the IPAC-RS Cascade Impactor Working Group IPAC-RS 2011 Conference 1 CI WG Members 1. Steve Stein 3M 2. Mårten Svenson AstraZeneca
More information